A6CDQ is a human organic cation transporter ( hOCT ) inhibitor with antidepressant-like activity that can cross the blood-brain barrier. A6CDQ potently inhibits the transport activities mediated by hOCT1, hOCT2 and hOCT3. A6CDQ exhibits significant antidepressant-like effects in the mouse tail suspension test. A6CDQ can be used in studies related to depression [1].
In Vivo, A6CDQ (0.1-30 mg/kg; i.p.; single dose) exhibits antidepressant-like activity in the mouse tail suspension test with an ED50 of 0.23 mg/kg[1].
In Vitro, A6CDQ (10-8-10-3 M; 1 min) inhibits hOCT1, hOCT2, and hOCT3-mediated MPP+ transport in stably transfected HEK293 cells, with IC50 values of 3.0 μM (hOCT1), 16.4 μM (hOCT2), and 3.9 μM (hOCT3)[1].
References:
[1]. Iyer KA, et al. The 2-Amino-3,4-dihydroquinazoline Molecular Scaffold as Novel OCT3 Inhibitor. ACS Chem Neurosci. 2026;17(7):1375-1386.
In Vivo, A6CDQ (0.1-30 mg/kg; i.p.; single dose) exhibits antidepressant-like activity in the mouse tail suspension test with an ED50 of 0.23 mg/kg[1].
In Vitro, A6CDQ (10-8-10-3 M; 1 min) inhibits hOCT1, hOCT2, and hOCT3-mediated MPP+ transport in stably transfected HEK293 cells, with IC50 values of 3.0 μM (hOCT1), 16.4 μM (hOCT2), and 3.9 μM (hOCT3)[1].
References:
[1]. Iyer KA, et al. The 2-Amino-3,4-dihydroquinazoline Molecular Scaffold as Novel OCT3 Inhibitor. ACS Chem Neurosci. 2026;17(7):1375-1386.